Document is current

Article History

Received: 17 May 2024

Accepted: 12 August 2024

First Online: 8 October 2024

Declarations

:

: The trial was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the institutional review board of Memorial Sloan Kettering Cancer Center, New York, USA (IRB #17–315). Informed consent was obtained from all individual participants included in the study.

: Informed consent was obtained from all individual participants included in the study.

: SM. Larson reports receiving commercial research grants from Y-mAbs Therapeutics, Inc., Genentech, Inc., WILEX AG, Telix Pharmaceuticals Limited, and Regeneron Pharmaceuticals, Inc.; holding ownership interest/equity in Elucida Oncology, Inc., and holding stock in ImaginAb, Inc., and Y-mAbs Therapeutics. SML is the inventor of issued patents both currently unlicensed and licensed by MSK to Samus Therapeutics, Inc., Elucida Oncology, Inc., and Y-mAbs Therapeutics, Inc. SML serves or has served as a consultant both compensated and uncompensated to Cynvec LLC, Eli Lilly & Co., Prescient Therapeutics Limited, Advanced Innovative Partners, LLC, Gerson Lehrman Group, Progenics Pharmaceuticals, Inc., Exini, Inc., and Janssen Pharmaceuticals, Inc. ALH relevant disclosures (over the last 3 years): serves as the principle investigator on clinical trials from AstraZeneca, Genentech, Merck, Bayer, Novartis, Celldex, Bristol-Meyer Squibb, Kura Oncology, Elevar Therapeutics, Astellas, Poseida Therapeutics, Bioatla, OncC4, and Ayala. ALH has served on advisory boards or performed consulting for Kura Oncology, Elevar Therapeutics, Prelude Therapeutics, Eisai, Exelixis, Merck, Rgenta, Remix Therapeutics, Cellestia, Inxmed, and Ayala. ALH serves on data and safety monitoring committees for Kura Oncology and Affyimmune Therapeutics. ALH is listed as an inventor on an MSK-issued patent for using lesional dosimetry methods for tailoring targeted radiotherapy in cancer.